Editorial policy

Peptide information needs evidence context.

Peptides Media covers how peptides are studied, discussed, sold, and used. The standard is clear writing, source quality, and clear separation between what is known, what is plausible, and what is still guesswork.

Principles

Human data is separated from preclinical signals

Each claim is grounded in its source type: randomized human trials, observational human data, animal work, in vitro work, or anecdote.

Study and real-world use context is named

Study doses, product labels, clinic claims, forum patterns, and gray-market references are identified for what they are, instead of being flattened into one claim.

Regulation and product quality stay close to the claim

A peptide can have a plausible mechanism and still have supply, labeling, purity, or legal problems. Those details belong next to the practical discussion, not buried elsewhere.

Source quality is part of the article

Primary studies, labels, regulator pages, trial listings, reviews, clinic material, and forum reports carry different weight.

Disclosure model

Articles show who wrote them and where the sources come from.

Articles identify authors, reviewers when listed, conflicts, and the sources behind the claims being discussed.

Peptides Media is an independent editorial desk. Research, drafting, and source collection are AI-assisted and checked against primary sources before publication; pages are not individually reviewed by a named clinician.

Peptides Media does not sell placement or affiliate recommendations. If that changes, the affected pages will say so plainly.